North America
South America
Australia & New Zealand
Europe
Middle East / Africa
Asia / Pacific
×
×
PCD CE/IVD

PCD 

Clone  JS-81  SJ25C1 (also known as SJ25-C1)  104D2  2D1  MI15  HB7  L293  L128   (CE/IVD)

  • Brand BD OneFlow™
  • Reactivity Human (QC Testing) 
  • Application Flow cytometry (Routinely Tested) 
  • Regulatory Status CE/IVD
Product Details Recommended Assay References

Description

The BD OneFlow™ PCD (Plasma Cell Disorders) tube, when run in parallel with the BD OneFlow™ PCST (Plasma Cell Screening Tube), is intended for flow-cytometric immunophenotyping of normal and aberrant plasma cells in bone marrow as an aid in the diagnosis of multiple myeloma and other plasma cell disorders. The BD OneFlow PCD tube is designed for use with a suitably equipped BD flow cytometer and software designated for in vitro diagnostic use.

Contents

Specificity Clone Format Isotype Entrez Gene ID
CD81 (TAPA-1) JS-81 APC-H7 IgG1, κ 975
CD19 SJ25C1 (also known as SJ25-C1) PE-Cy™7 IgG1, κ 930
CD117 (c-Kit) 104D2 APC IgG1 3815
CD45 2D1 V450 IgG1, κ
CD138 (Syndecan-1) MI15 V500-C IgG1, κ 6382
CD38 HB7 FITC IgG1, κ 952
CD28 L293 PE IgG1, κ 940
CD27 L128 PerCP-Cy™5.5 IgG1 939
Resources & Tools
 Spectrum Viewer  IFU  Regulatory Document Website
Preparation and Storage

Store tubes at 2°C–27°C in the foil pouch. Do not freeze the reagent or expose it to direct light at any time during storage or incubation with cells. The dried fluorochrome-conjugated antibodies are stable until the expiration date shown on the pouch and tube labels when stored as directed. Do not use after the expiration date. Once the pouch is opened, the dried fluorochrome-conjugated antibodies are stable for one month when stored as directed.

CAUTION Ensure that the pouch is completely resealed after removing a tube. The reagent is very sensitive to moisture. Do not remove the desiccant from the reagent pouch.


  1. Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline—Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.

  2. Appendix C. Summary of antibody names, code numbers, and donor laboratories. In: McMichael AJ, Beverley PC, Cobbold S, et al, eds. Leucocyte Typing III: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1987:988-993.

  3. Ashman LK, Cambareri AC, Nguyen L, Bühring H-J. CD117 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AEG, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing, Inc; 1997:816-818.

  4. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.

  5. Cobbold SP, Hale G, Waldmann H. Non-lineage, LFA-1 family, and leucocyte common antigens: new and previously defined clusters. In: McMichael AJ, Beverley PC, Cobbold S, et al, eds. Leucocyte Typing III: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1987:788-803.

  6. Horvathova M, Gaillard JP, Liautard J, et al. Identification of novel and specific antigens of human plasma cells by mAb. In: Schlossman S, Boumsell L, Gilks W, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:713-714.

  7. Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986-2010.

  8. Kobata T, Morimoto C. CD27 Workshop Panel Report. In: Kishimoto T, Kikutani H, von dem Borne AE, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing, Inc.; 1997:67-69.

  9. Ling NR, Maclennan ICM, Mason DY. B-cell and plasma cell antigens: new and previously defined clusters. In: McMichael AJ, Beverley PC, Cobbold S, et al, eds. Leucocyte Typing III: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1987:302-335.

  10. Nadler LM. B Cell/Leukemia Panel Workshop: Summary and Comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. Vol 2. New York, NY: Springer-Verlag; 1986:3-43.

  11. Olive D, Cerdan C, Costello R, et al. CD28 and CTLA-4 cluster report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:360-370.

  12. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-895.

  13. Tedder TF, Wagner N, Engel P. CD81 Workshop report. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. Leukocyte Typing V: White Cell Differentiation Antigens. Vol 1. New York, NY: Oxford University Press; 1995:684-688.

  14. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908-1975.

  15. Wijdenes J, Clément C, Klein B, Dore J-M. CD138 (syndecan-1) Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AE, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing, Inc; 1997:249-252.

659913 Rev.
Instruments
Reagents
Applications
Sales & Support
BD BioSciences